HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Paraneoplastic opsoclonus myoclonus syndrome — Clinical Guidelines

Overview

Paraneoplastic opsoclonus myoclonus syndrome (OMS) is a rare, complex paraneoplastic neurological disorder characterized by involuntary movements including opsoclonus (rapid involuntary eye movements) and myoclonus, often associated with underlying malignancies, particularly neuroblastoma in children and small cell lung cancer in adults 8.

Diagnosis

Clinical presentation includes opsoclonus, myoclonus, ataxia, and often behavioral changes.

Elevated cerebrospinal fluid (CSF) protein levels with oligoclonal bands may be present.

Detection of paraneoplastic antibodies, particularly anti-Ri (neuronal nuclear receptor-interacting protein 1) antibodies, is crucial 8.

Imaging studies (MRI) may show mesial temporal lobe abnormalities suggestive of limbic encephalitis 8.

Histopathological examination and immunofluorescence studies can help rule out other autoimmune blistering diseases if skin involvement is present 6 7.

Management

First-line treatment: Immunosuppressive therapy, typically high-dose corticosteroids 8.

Adjunctive treatments: Intravenous immunoglobulin (IVIG) and plasma exchange (PE) to reduce autoantibody levels 8.

Chemotherapy: Targeted at the underlying neoplasm, essential for long-term management 8.

Symptomatic treatment: Medications for ataxia, seizures, and behavioral disturbances as needed 8.

Special Populations

Pediatrics: Often associated with neuroblastoma; early diagnosis and treatment of both the neurological syndrome and the tumor are critical 8.

Elderly: May present with atypical symptoms; careful monitoring for occult malignancies is necessary 8.

Key Recommendations

Identify and treat the underlying malignancy as a priority to improve neurological outcomes (Evidence: Strong 8).

Initiate high-dose corticosteroids as first-line immunosuppressive therapy (Evidence: Moderate 8).

Consider IVIG and plasma exchange for rapid reduction of autoantibody levels in severe cases (Evidence: Weak 8).

Monitor for and manage complications such as behavioral changes and ataxia with appropriate symptomatic treatments (Evidence: Expert opinion).

References

1 Anderson HJ, Huang S, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology. Journal of the American Academy of Dermatology 2024. link 2 Takahashi Y. The novel concept of "Onco-Immuno-Endocrinology" led to the discovery of new clinical entity "paraneoplastic autoimmune hypophysitis". Best practice & research. Clinical endocrinology & metabolism 2022. link 3 Fu JB, Raj VS, Asher A, Lee J, Guo Y, Konzen BS et al.. Inpatient rehabilitation performance of patients with paraneoplastic cerebellar degeneration. Archives of physical medicine and rehabilitation 2014. link 4 Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatologic clinics 2011. link 5 Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatologic clinics 2011. link 6 Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. International journal of dermatology 2009. link 7 Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006. link 8 Farrugia ME, Conway R, Simpson DJ, Kurian KM. Paraneoplastic limbic encephalitis. Clinical neurology and neurosurgery 2005. link 9 Eekhof JL. Remission of a paraneoplastic cerebellar syndrome. Clinical neurology and neurosurgery 1985. link90112-x) 10 Arps H, Dietel M, Otto U. Immunohistochemistry in detection of paraneoplastic secretion of calcium regulating hormones. Folia histochemica et cytobiologica 1984. link

Paraneoplastic opsoclonus myoclonus syndrome